It is hypothesised that the high incidence of bleeding associated with ibrutinib use in CLL is due to a pre-existing and under-recognised mild platelet function defect exacerbated by platelet BTK inhibition [15]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.